اخبار و اعلانات

 آمار

تعداد نشریات284
تعداد نشریات سازمان82
تعداد شماره‌ها3,050
تعداد مقالات34,085
تعداد مشاهده مقاله46,557,255
تعداد دریافت فایل اصل مقاله77,610,434
Merza, Mohammed. (1403). Serological Studies of IgG and IgM in Response to SARS-CoV-2 Vaccination in Erbil, Kurdistan-Iraq. سامانه مدیریت نشریات علمی, 80(1), 249-255. doi: 10.32592/ARI.2025.80.1.249
Mohammed Yousif Merza. "Serological Studies of IgG and IgM in Response to SARS-CoV-2 Vaccination in Erbil, Kurdistan-Iraq". سامانه مدیریت نشریات علمی, 80, 1, 1403, 249-255. doi: 10.32592/ARI.2025.80.1.249
Merza, Mohammed. (1403). 'Serological Studies of IgG and IgM in Response to SARS-CoV-2 Vaccination in Erbil, Kurdistan-Iraq', سامانه مدیریت نشریات علمی, 80(1), pp. 249-255. doi: 10.32592/ARI.2025.80.1.249
Merza, Mohammed. Serological Studies of IgG and IgM in Response to SARS-CoV-2 Vaccination in Erbil, Kurdistan-Iraq. سامانه مدیریت نشریات علمی, 1403; 80(1): 249-255. doi: 10.32592/ARI.2025.80.1.249

Serological Studies of IgG and IgM in Response to SARS-CoV-2 Vaccination in Erbil, Kurdistan-Iraq

Archives of Razi Institute
مقاله 30، دوره 80، شماره 1، فروردین و اردیبهشت 2025، صفحه 249-255    اصل مقاله (377.6 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.32592/ARI.2025.80.1.249
نویسنده
Mohammed Yousif Merza*
Department of Clinical Analysis College of Pharmacy Hawler Medical University, Erbil, Kurdistan 100M street Erbil, Iraq
چکیده
The current pandemic of coronavirus disease (COVID-19) has brought significant challenges to healthcare systems and economies globally. COVID-19 vaccines aim to generate immune responses against the SARS-CoV-2 spike protein, ideally neutralizing antibodies. Efficacy has now been documented for several vaccinations, including mRNA, adenoviral-vectored protein subunit, and whole-cell inactivated subunit vaccines. Understanding the immune responses to COVID-19 vaccines and how different antibodies are created after vaccination is critical to better understanding the pathophysiology of COVID-19. In the current study, humoral immune responses that elicited by BNT162b2 (mRNA-based), BBIBP-CorV (inactivated virus), and ChAdOx1 (dsDNA-recombinant based) vaccines against SARS-CoV-2 virus were compared. A total of three hundred and twenty-one individuals were included in this study, in which 90 individuals have taken no vaccines (control group) and post vaccinated with Pfizer, and Sinopharm each 77 participants, respectively. Blood samples were collected after 10 weeks vaccination and serum was analysed. The human SARS-CoV-2 Spike (Trimer) IgG or IgM ELISA (Thermo Fisher) were used to measure the amount of IgG or IgM antibodies bound to SARS-CoV-2 Spike (Trimer). it was found that statistically there is no significant difference between the vaccines (P value =0.958). The study found all three vaccines (Pfizer, AstraZeneca and Sinopharm) were effective in the production of IgM and IgG. This study showed that Sinopharm is more effective in the production of IgM and IgG. the usage of ChAdOx1 has led to the production of more IgG compared to BNT162b2 as statistically it was found to be significantly different (P value= 0.0001). Sinopharm's generation of a stronger immune system may result from the fact that it's an inactivated subunit vaccine. The immunological reactions to the vaccines studied in the following studies have prompted a lot of issues about how they happen. The study recommends more studies regarding the most effective vaccines among Kurdish people in Kurdistan Region of Iraq.
کلیدواژه‌ها
SARS-CoV-2؛ Covid-19؛ IgM؛ IgG؛ Vaccines
مراجع
  1. Shen L, Wang C, Zhao J, Tang X, Shen Y, Lu M, et al. Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression. Emerg Microbes Infect. 2020;9(1):1096–101.
  2. Merza MY, Hwaiz RA, Hamad BK, Mohammad KA, Hama HA, Karim AY. Analysis of cytokines in SARS-CoV-2 or COVID-19 patients in Erbil city, Kurdistan Region of Iraq. PLoS One. 2021;16(4 April):e0250330.
  3. Hwaiz R, Merza M, Hamad B, HamaSalih S, Mohammed M, Hama H. Evaluation of hepatic enzymes activities in COVID-19 patients. Int Immunopharmacol. 2021;97:107701.
  4. Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–54.
  5. Najafimehr H, Mohamed Ali K, Safari S, Yousefifard M, Hosseini M. Estimation of basic reproduction number for COVID-19 and the reasons for its differences. Int J Clin Pract. 2020;74(8).
  6. Gong W, Aspatwar A, Wang S, Parkkila S, Wu X. COVID-19 pandemic: SARS-CoV-2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials. Expert Rev Vaccines. 2021;20(7):857–80.
  7. Hurt AC, Wheatley AK. Neutralizing antibody therapeutics for covid-19. Viruses. 2021;13(4):628.
  8. Awadasseid A, Wu Y, Tanaka Y, Zhang W. Current advances in the development of sars-cov-2 vaccines. Int J Biol Sci. 2021;17(1):8–19.
  9. Pang NYL, Pang ASR, Chow VT, Wang DY. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Mil Med Res. 2021;8(1):47.
  10. Shah VK, Firmal P, Alam A, Ganguly D, Chattopadhyay S. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. Front Immunol. 2020;11:553450.
  11. Hellerstein M. What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2? Vaccine X. 2020;6:100076.
  12. Röltgen K, Boyd SD. Antibody and B Cell Responses to SARS-CoV-2 Infection and Vaccination: The End of the Beginning. Annu Rev Pathol Mech Dis. 2024;19(7):69–97.
  13. Zhang Y, Li D, Zhao H, Wang L, Liao Y, Li X, et al. The role of multiple SARS-CoV-2 viral antigens in a vaccine-induced integrated immune response. Vaccine. 2021;39(18):2500–3.
  14. Matchett WE, Joag V, Stolley JM, Shepherd FK, Quarnstrom CF, Mickelson CK, et al. Cutting Edge: Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity. J Immunol. 2021;207(2):376–9.
  15. Vályi-Nagy I, Matula Z, Gönczi M, Tasnády S, Bekő G, Réti M, et al. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans. Geroscience. 2021;43(5):2321–31.
آمار
تعداد مشاهده مقاله: 254
تعداد دریافت فایل اصل مقاله: 235


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب